Performance of Cervical Screening a Decade Following HPV Vaccination: The Costa Rica Vaccine Trial.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
09 09 2022
09 09 2022
Historique:
received:
03
12
2021
revised:
26
03
2022
accepted:
18
05
2022
pubmed:
1
6
2022
medline:
15
9
2022
entrez:
31
5
2022
Statut:
ppublish
Résumé
We investigated the impact of human papillomavirus (HPV) vaccination on the performance of cytology-based and HPV-based screening for detection of cervical precancer among women vaccinated as young adults and reaching screening age. A total of 4632 women aged 25-36 years from the Costa Rica HPV Vaccine Trial were included (2418 HPV-vaccinated as young adults and 2214 unvaccinated). We assessed the performance of cytology- and HPV-based cervical screening modalities in vaccinated and unvaccinated women to detect high-grade cervical precancers diagnosed over 4 years and the absolute risk of cumulative cervical precancers by screening results at entry. We detected 95 cervical intraepithelial neoplasia grade 3 or worse (52 in unvaccinated and 43 in vaccinated women). HPV16/18/31/33/45 was predominant (69%) among unvaccinated participants, and HPV35/52/58/39/51/56/59/66/68 predominated (65%) among vaccinated participants. Sensitivity and specificity of cervical screening approaches were comparable between women vaccinated as young adults and unvaccinated women. Colposcopy referral rates were lower in the vaccinated group for HPV-based screening modalities, but the positive predictive value was comparable between the 2 groups. Among women approaching screening ages, vaccinated as young adults, and with a history of intensive screening, the expected reduction in the positive predictive value of HPV testing, associated with dropping prevalence of HPV-associated lesions, was not observed. This is likely due to the presence of high-grade lesions associated with nonvaccine HPV types, which may be less likely to progress to cancer.
Sections du résumé
BACKGROUND
We investigated the impact of human papillomavirus (HPV) vaccination on the performance of cytology-based and HPV-based screening for detection of cervical precancer among women vaccinated as young adults and reaching screening age.
METHODS
A total of 4632 women aged 25-36 years from the Costa Rica HPV Vaccine Trial were included (2418 HPV-vaccinated as young adults and 2214 unvaccinated). We assessed the performance of cytology- and HPV-based cervical screening modalities in vaccinated and unvaccinated women to detect high-grade cervical precancers diagnosed over 4 years and the absolute risk of cumulative cervical precancers by screening results at entry.
RESULTS
We detected 95 cervical intraepithelial neoplasia grade 3 or worse (52 in unvaccinated and 43 in vaccinated women). HPV16/18/31/33/45 was predominant (69%) among unvaccinated participants, and HPV35/52/58/39/51/56/59/66/68 predominated (65%) among vaccinated participants. Sensitivity and specificity of cervical screening approaches were comparable between women vaccinated as young adults and unvaccinated women. Colposcopy referral rates were lower in the vaccinated group for HPV-based screening modalities, but the positive predictive value was comparable between the 2 groups.
CONCLUSIONS
Among women approaching screening ages, vaccinated as young adults, and with a history of intensive screening, the expected reduction in the positive predictive value of HPV testing, associated with dropping prevalence of HPV-associated lesions, was not observed. This is likely due to the presence of high-grade lesions associated with nonvaccine HPV types, which may be less likely to progress to cancer.
Identifiants
pubmed: 35640980
pii: 6596052
doi: 10.1093/jnci/djac107
pmc: PMC9468298
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1253-1261Informations de copyright
Published by Oxford University Press 2022.
Références
BMJ. 2019 Apr 3;365:l1161
pubmed: 30944092
Int J Cancer. 2019 Jan 1;144(1):34-42
pubmed: 29943809
Int J Cancer. 2017 Aug 15;141(4):701-710
pubmed: 28500655
Am J Epidemiol. 2013 Sep 1;178(5):752-60
pubmed: 23843026
J Infect Dis. 2019 Oct 8;220(10):1609-1619
pubmed: 31536132
Eur J Cancer. 2018 Mar;91:68-75
pubmed: 29335156
Int J Cancer. 2018 Oct 1;143(7):1662-1670
pubmed: 29707775
Prev Med. 2019 Jan;118:44-50
pubmed: 30316878
Cancer Discov. 2011 Oct;1(5):408-19
pubmed: 22586631
Br J Cancer. 2016 Mar 1;114(5):582-9
pubmed: 26931370
Int J Cancer. 2016 Dec 1;139(11):2606-15
pubmed: 27509172
Lancet Oncol. 2014 Mar;15(3):315-22
pubmed: 24529697
J Clin Microbiol. 2019 Jan 2;57(1):
pubmed: 30355760
J Clin Microbiol. 2012 Feb;50(2):300-6
pubmed: 22162556
CMAJ. 2013 Aug 6;185(11):E537-44
pubmed: 23798453
Cochrane Database Syst Rev. 2017 Aug 10;8:CD008587
pubmed: 28796882
Lancet. 2020 Feb 22;395(10224):575-590
pubmed: 32007141
JAMA. 2018 Jul 3;320(1):43-52
pubmed: 29971397
BMJ Open. 2015 Aug 14;5(8):e007921
pubmed: 26275901
J Low Genit Tract Dis. 2020 Apr;24(2):90-101
pubmed: 32243306
Int J Cancer. 2016 Jun 15;138(12):2922-31
pubmed: 26845632
J Low Genit Tract Dis. 2020 Apr;24(2):102-131
pubmed: 32243307
Br J Cancer. 2020 Jul;123(1):155-160
pubmed: 32362659
Int J Cancer. 2019 Oct 15;145(8):2042-2050
pubmed: 30684396
J Clin Microbiol. 2008 Aug;46(8):2595-604
pubmed: 18579716
JAMA Oncol. 2021 Feb 01;7(2):263-270
pubmed: 33377903
Int J Cancer. 2007 Aug 1;121(3):621-32
pubmed: 17405118
Lancet Public Health. 2017 Feb;2(2):e96-e107
pubmed: 29253402
PLoS Med. 2017 Sep 19;14(9):e1002388
pubmed: 28926579
J Natl Cancer Inst. 2019 Sep 1;111(9):923-932
pubmed: 30629194
CA Cancer J Clin. 2020 Sep;70(5):321-346
pubmed: 32729638
Int J Cancer. 2014 Apr 15;134(8):1835-43
pubmed: 24122508
Lancet. 2019 Aug 10;394(10197):497-509
pubmed: 31255301
Vaccine. 2008 Sep 2;26(37):4795-808
pubmed: 18640170
J Natl Cancer Inst. 2016 Oct 18;109(2):
pubmed: 27754955
JAMA. 2002 Apr 24;287(16):2114-9
pubmed: 11966386
Cancer Epidemiol Biomarkers Prev. 2017 Nov;26(11):1629-1635
pubmed: 28887297
Gynecol Oncol. 2014 May;133(2):172-9
pubmed: 24631450
Int J Cancer. 2013 Feb 15;132(4):916-23
pubmed: 22684726
Cochrane Database Syst Rev. 2018 May 09;5:CD009069
pubmed: 29740819
Clin Epigenetics. 2019 Oct 12;11(1):140
pubmed: 31606044
BJOG. 2017 Aug;124(9):1386-1393
pubmed: 28102928
Vaccine. 2015 Apr 27;33(18):2141-51
pubmed: 25796338